Given the overwhelming evidence showing CSF p-tau to be a robust biomarker for AD, the question lies with whether plasma p-tau correlates as strongly with Aβ pathology, and whether there is scope for plasma p-tau to function as a biomarker of Aβ pathology better than Aβ biomarkers. Here, MAPT is linked to Alzheimer disease.